Brokerages Set Calian Group Ltd. (TSE:CGY) Target Price at C$73.43

Shares of Calian Group Ltd. (TSE:CGY) have been given an average rating of “Buy” by the six brokerages that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued ratings on the stock in the last year is C$74.83.

A number of analysts recently weighed in on the company. Acumen Capital lifted their price target on Calian Group from C$70.00 to C$85.00 and gave the company a “buy” rating in a research note on Friday. Canadian Imperial Bank of Commerce boosted their target price on shares of Calian Group from C$65.00 to C$76.00 in a research report on Friday. Royal Bank Of Canada upped their price target on shares of Calian Group from C$58.00 to C$60.00 and gave the stock an “outperform” rating in a research note on Friday. Desjardins increased their price target on shares of Calian Group from C$59.00 to C$66.00 and gave the company a “buy” rating in a report on Thursday, November 27th. Finally, Ventum Financial boosted their price objective on shares of Calian Group from C$72.00 to C$82.00 and gave the stock a “buy” rating in a report on Friday.

Calian Group Trading Up 6.7%

TSE CGY opened at C$70.60 on Friday. The stock has a market capitalization of C$805.62 million, a P/E ratio of 30.96, a P/E/G ratio of 2.50 and a beta of 0.70. Calian Group has a 52-week low of C$37.70 and a 52-week high of C$71.92. The firm has a 50-day moving average price of C$60.38 and a 200 day moving average price of C$54.15. The company has a quick ratio of 1.20, a current ratio of 1.29 and a debt-to-equity ratio of 39.54.

Calian Group (TSE:CGY) last announced its quarterly earnings data on Thursday, February 12th. The company reported C$1.03 earnings per share for the quarter. The company had revenue of C$208.00 million for the quarter. Calian Group had a return on equity of 3.37% and a net margin of 1.50%. Equities research analysts expect that Calian Group will post 4.9475219 EPS for the current year.

Calian Group Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 11th. Stockholders of record on Wednesday, March 11th will be paid a dividend of $0.28 per share. The ex-dividend date of this dividend is Wednesday, February 25th. This represents a $1.12 annualized dividend and a dividend yield of 1.6%. Calian Group’s payout ratio is 49.12%.

Key Headlines Impacting Calian Group

Here are the key news stories impacting Calian Group this week:

• Positive Sentiment: Record Q1 results — Calian reported C$208M revenue (up ~12% YoY) with margin gains and C$1.03 EPS, and management signaled confident growth on the earnings call; this strengthens the growth narrative driving buying interest. Calian Delivers Record Q1 Revenue and Margin Gains
• Positive Sentiment: Multiple analyst target upgrades — Acumen (to C$85, Buy), Canaccord (to C$80), CIBC (to C$76) and Ventum (to C$82, Buy) raised price targets, signaling broad analyst optimism and providing upward catalyst for the stock. Analyst Ratings Roundup
• Positive Sentiment: Quarterly dividend declared — Board approved a C$0.28 quarterly dividend (annualized yield ~1.6%), with ex-dividend Feb 25 and record Mar 11; supports shareholder return profile and can attract income-minded buyers.
• Neutral Sentiment: Corporate governance update — Shareholders re‑elected the board and named Valerie Sorbie as Chair, which preserves leadership continuity but is unlikely to move the stock materially by itself. Shareholder Meeting Results
• Negative Sentiment: RBC’s moderate target bump to C$60 — Although RBC maintained an “outperform” stance, its target remains well below the current price, indicating at least one major analyst sees less upside and creating potential resistance or caution among some investors. RBC Target Update

Calian Group Company Profile

Calian Group Ltd operates through four segments namely Advanced Technologies, Health, Learning, and Information Technology. It generates maximum revenue from the Health segment. The company serves health, defence, security, aerospace, engineering, AgTech, and IT industries. Its Health segment includes Clinical Services; Nursing Services; Psychological Services and Medical Property Management. The Advanced Technologies segment includes Engineering Solutions and Services; Nuclear and Environmental Services; Satcom; DOCSIS; Electronics Design and Manufacturing and Agricultural Technology.